Cash and cash equivalents (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventory, net (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease rights of use (USD, thousands)

Software license inventory (USD, thousands)

Licensing rights (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued compensation (USD, thousands)

Other accrued liabilities (USD, thousands)

Operating lease liabilities, current portion (USD, thousands)

Deferred product and service revenue, current portion (USD, thousands)

2020 senior secured convertible note payable, net (USD, thousands)

Total current liabilities (USD, thousands)

Operating lease liabilities, net of current portion (USD, thousands)

Deferred product and service revenue, net of current portion (USD, thousands)

Total liabilities (USD, thousands)

Common stock, $ 0.01 par value; 90,000,000 shares authorized at December 31, 2024 and 2023; shares issued and outstanding at December 31, 2024 and 2023, respectively (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

b54f3f77a41185a45e7159660158f26df60cf4833985f793de6e1a48b03b5dab

Product revenue (USD, thousands)

Service and other revenue (USD, thousands)

Total revenue (USD, thousands)

Cost of revenue (USD, thousands)

Gross profit (USD, thousands)

Research and development costs (USD, thousands)

Sales and marketing expenses (USD, thousands)

General and administrative expenses (USD, thousands)

Operating loss (USD, thousands)

Other expense, net (USD, thousands)

Interest income, net (USD, thousands)

Net loss (USD, thousands)

Net loss per share attributable to common stockholders, Basic and diluted (USD)

Weighted average shares outstanding, Basic and diluted

2eb331a6908f988532c01acf1cf2dcfa0e3ba498ae3599ed207abc2d7584f30e

Number of new global centers activated (count)

ed073eb69f91b1d402751cb7477839d53b381fbb9206bc8119204c69a3b61ec1

Net Loss (USD, thousands)

Depreciation and Amortization (USD, thousands)

Share-Based Compensation (USD, thousands)

Amortization of Debt Issuance Costs and Original Issue Discounts (USD, thousands)

Amortization of Lease Right of Use Assets, Net of Accretion in Lease Liabilities (USD, thousands)

Accretion of Discounts on Short-Term Investments (USD, thousands)

Net Cash Flows from Operating Activities (USD, thousands)

Purchases of Property and Equipment (USD, thousands)

Acquisition of Licensing Rights (USD, thousands)

Proceeds from Maturities of Short-Term Investments (USD, thousands)

Net Cash Flows from Investing Activities (USD, thousands)

Proceeds from Public Offering of Common Stock, Net of Offering Costs (USD, thousands)

Repayment of 2020 Senior Secured Convertible Note (USD, thousands)

Proceeds from Stock Option Exercises (USD, thousands)

Proceeds from Issuance of Common Stock Under Employee Stock Purchase Plan (USD, thousands)

Payments for Taxes Related to Net Share Settlement of Equity Awards (USD, thousands)

Net Cash Flows from Financing Activities (USD, thousands)

Net Change in Cash and Cash Equivalents (USD, thousands)

Income Taxes Paid (USD, thousands)

Interest Paid (USD, thousands)

Allowance for Credit Losses (Recoveries) (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory, Net (USD, thousands)

Prepaid Expenses and Other Current Assets (USD, thousands)

Other Assets (USD, thousands)

Accounts Payable and Accrued Expenses (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Revenue (USD, thousands)

Cash and Cash Equivalents, Beginning of Year (USD, thousands)

Cash and Cash Equivalents, End of Year (USD, thousands)

1c0add981042b48dbdcb066ebb3af8e01899fe816d3638ef17ff687351664655

Biologics and Drug Delivery

- Disposable Products

- Services and License Fees

Neurosurgery Navigation and Therapy

- Services

Capital Equipment and Software

- Systems and Software Products

Total Revenue

83681acbf480ee1bbeb70f737e6f21a4b747999999173c02c47f1cfadc979cff

ClearPoint Neuro (CLPT)

Financials